- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07673614
Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors
Improving Sensorimotor Function in CIPN: A Randomized, Sham Controlled, Double Blinded, Crossover Mechanistic Trial of Transcranial Direct Current to the Sensorimotor Cortex
This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Eshaka Eshwar
- Telefonnummer: 734-232-5901
- E-mail: eshaka@med.umich.edu
Studiesteder
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- University of Michigan Rogel Cancer Center
-
Ledende efterforsker:
- Brendan L. McNeish
-
Kontakt:
- Eshaka Eshwar
- Telefonnummer: 734-232-5901
- E-mail: eshaka@med.umich.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 18 to 85 years of age
- Diagnosis of cancer, stages I-IV
- Cancer survivor (not currently receiving chemotherapy, radiation, or immunotherapy)
- Presence of CIPN defined as new, length-dependent numbness, tingling, and/or pain that developed with neurotoxic chemotherapy
- CIPN20 score ≥ 20
- Able to walk unassisted
- Proficient in English
Exclusion Criteria:
- Known brain metastases
- Known neurological conditions aside from chemotherapy-induced peripheral neuropathy (CIPN)
- History of brain or spinal surgery
- Neuropathy other than CIPN
- Significant hearing or vision deficits
- Vestibulopathy
- Currently receiving chemotherapy, radiation therapy, or immunotherapy
- Contraindications to transcranial direct current stimulation (tDCS), including recent seizures
- Presence of metallic objects in the head
- Presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices)
- Active scalp dermatological conditions
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Arm I (active tDCS)
Patients undergo tDCS to the sensorimotor cortex, using the Starstim-8™ system, for 20 minutes. One week later, patients cross-over to Arm II. |
Ancillary studies Undergo tDCS
Andre navne:
|
|
Sham-komparator: Arm II (sham tDCS)
Patients undergo sham tDCS to the sensorimotor cortex, using the Starstim-8™ system, for 20 minutes. One week later, patients cross-over to Arm I. |
Ancillary studies Undergo sham tDCS
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Vibration detection threshold
Tidsramme: at weeks 2 and 3
|
Assessed via Vibration Detection Threshold (CASE IV): Quantitative sensory testing (QTS) for large fiber function. Will conduct a series of two-way analysis of variance (ANOVAs) with each of the vibratory thresholds, cold thresholds, and physical function measures as the dependent variables. Group (active transcranial direct current stimulation [tDCS] versus sham tDCS) and time (baseline, immediate post) will be included as fixed factors of interest along with their interaction to assess treatment effects over time. |
at weeks 2 and 3
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cold detection threshold
Tidsramme: at weeks 2 and 3
|
Assessed via Cold Detection Threshold (CASE IV): QST for small fiber function. Will conduct a series of two-way ANOVAs with each of the vibratory thresholds, cold thresholds, and physical function measures as the dependent variables. Group (active tDCS versus sham tDCS) and time (baseline, immediate post) will be included as fixed factors of interest along with their interaction to assess treatment effects over time. |
at weeks 2 and 3
|
|
Correlation between executive function and chemotherapy-induced peripheral neuropathy (CIPN) severity
Tidsramme: At baseline
|
Assessed with European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN20. Will use multivariable models with CIPN20 as the dependent variable, executive function as the primary predictor, and sural amplitude as a covariate. Additional covariates will include age, sex, depression, and pain. |
At baseline
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Brendan L McNeish, University of Michigan Rogel Cancer Center
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- UMCC 2025.097
- NCI-2026-03995 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- HUM00276508 (Anden identifikator: University of Michigan Rogel Cancer Center)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .